JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB269494

Human CD55 knockout MCF7 cell line

Be the first to review this product! Submit a review

|

(0 Publication)

CD55 KO cell line available to order. KO validated by Next Generation Sequencing. Free of charge wild type control available. Knockout achieved by CRISPR/Cas9; X = 1 bp insertion; Frameshift: 98%. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.

View Alternative Names

CD 55, CD55 Cromer blood group system, CD55 antigen, CD55 molecule, CD55 molecule (Cromer blood group), CD55 molecule, decay accelerating factor for complement (Cromer blood group), CR, CROM, Cd55a, Complement decay-accelerating factor, Complement decay-accelerating factor, GPI-anchored, Cromer Blood Group antigen, Cromer blood group system, DAF_HUMAN, Daf-GPI, Dcay accelerating factor for complement (CD55, Cromer blood group system), Decay Accelerating Factor for Complement, Decay accelarating factor 1, isoform CRA_a, Decay accelerating factor (GPI-form), Decay accelerating factor GPI-form, Decay accelerating factor soluble-form, GPI-DAF, TC

1 Images
Next Generation Sequencing - Human CD55 knockout MCF7 cell line (AB269494)
  • NGS

Supplier Data

Next Generation Sequencing - Human CD55 knockout MCF7 cell line (AB269494)

Knockout achieved by CRISPR/Cas9; X = 1 bp insertion; Frameshift : 98%

Key facts

Cell type

MCF7

Species or organism

Human

Tissue

Breast

Form

Liquid

form

Knockout validation

Next Generation Sequencing

Mutation description

Knockout achieved by CRISPR/Cas9; X = 1 bp insertion; Frameshift: 98%

Disease

Adenocarcinoma

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "NGS": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab269494-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab271144 Human wild-type MCF7 cell line", "number":"AB269494-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab269494 Human CD55 knockout MCF7 cell line", "number":"AB269494-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab269494-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab269494 Human CD55 knockout MCF7 cell line", "number":"AB269494-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
CD55
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Next Generation Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
-196°C|-80°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • Slow to trypsinise.
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 5-7x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

MEM + 10% FBS + 0.01 mg/ml bovine insulin

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

CD55 also known as Decay-Accelerating Factor (DAF) is a glycoprotein that regulates the complement cascade. This protein typically weighs around 70 kDa. It is expressed in many cells including epithelial and endothelial cells and is often present on the surface of blood cells. CD55 plays an important role in protecting cells against lysis by inhibiting the formation and stability of C3 and C5 convertases which ultimately prevent cell destruction by the complement system.
Biological function summary

CD55 helps maintain immune homeostasis by preventing the complement-mediated damage to host tissues. It functions as a member of the regulators of complement activation (RCA) family. While not necessarily part of a larger protein complex its function is related to other regulatory proteins such as CD46 and CD59 which cooperate to regulate complement activity. The DAF protein's immunology function is instrumental in ensuring that self-cells are not inadvertently attacked by the body's immune system.

Pathways

CD55 significantly impacts the complement pathway which is a central component of the innate immune system. It directly interacts with complement components C3 and C5 accelerating their decay and disassembly. Through this pathway CD55 has a working relationship with other complement regulatory proteins like Factor H which also aids in controlling complement activation on the cell surface.

A dysfunctional CD55 can relate to conditions such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). In PNH the absence or insufficiency of CD55 (and CD59) on red blood cells leads to complement-mediated lysis causing hemolytic anemia. In aHUS impaired regulation of the complement system including abnormalities in CD55 function exacerbates symptoms. CD55's role is therefore important in preventing these complement-related disorders and preserving cellular integrity in the human body.

Cell culture

Biosafety level

EU: 1 US: 1

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com